Novocure to Report Second Quarter 2024 Financial Results

Rhea-AI Summary

Novocure (NASDAQ: NVCR) will release its financial results for the second quarter of 2024 on July 25, 2024, before the U.S. markets open. A conference call and webcast are scheduled for the same day at 8:00 a.m. EDT to discuss the results. The webcast and accompanying slides will be accessible via the Investor Relations page on Novocure's website and will remain available for two weeks post-call.

Positive

• Scheduled release of Q2 2024 financial results provides transparency and allows investors to make informed decisions.
• Availability of a conference call and webcast offers investors direct insights from management.

Negative

• None.

ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three and six months ended June 30, 2024, at 8:00 a.m. EDT on Thursday, July 25, 2024. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “could” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240701586779/en/

Investors and Media:

Ingrid Goldberg

investorinfo@novocure.com

media@novocure.com

Source: Novocure

FAQ

When will Novocure release its Q2 2024 financial results?

Novocure will release its Q2 2024 financial results on July 25, 2024, before the U.S. markets open.

What is the stock symbol for Novocure?

The stock symbol for Novocure is NVCR.

How can investors access the Novocure Q2 2024 financial results conference call?

Investors can access the conference call via a provided registration link, with dial-in details to be given upon registration.

Will the Novocure Q2 2024 financial results webcast be available for later viewing?

Yes, the webcast and its slides will be available on the Investor Relations page of Novocure's website for at least 14 days following the call.

At what time is the Novocure Q2 2024 earnings call scheduled?

The earnings call is scheduled for 8:00 a.m. EDT on July 25, 2024.